

Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years

Solmaz Setayeshgar , Elaine Kingwell , Feng Zhu , Xinyu Zhang , Tingting Zhang , Ruth Ann Marrie , Robert Carruthers , Helen Tremlett

PII: S2211-0348(18)30221-9  
DOI: [10.1016/j.msard.2018.07.012](https://doi.org/10.1016/j.msard.2018.07.012)  
Reference: MSARD 887



To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 14 March 2018  
Revised date: 3 July 2018  
Accepted date: 6 July 2018

Please cite this article as: Solmaz Setayeshgar , Elaine Kingwell , Feng Zhu , Xinyu Zhang , Tingting Zhang , Ruth Ann Marrie , Robert Carruthers , Helen Tremlett , Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years, *Multiple Sclerosis and Related Disorders* (2018), doi: [10.1016/j.msard.2018.07.012](https://doi.org/10.1016/j.msard.2018.07.012)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Highlights**

- Little is known about the use of the new oral MS drugs in clinical practice
- Uptake for an oral MS drug was 16.6/1000 person-years over the five-year study period
- Uptake and use of the new oral DMTs increased substantially from 2011-2015
- Uptake and use of the oral MS drugs were similar for men and women
- However, subjects with a higher (vs. lower) socioeconomic status had a higher uptake

Download English Version:

<https://daneshyari.com/en/article/8647182>

Download Persian Version:

<https://daneshyari.com/article/8647182>

[Daneshyari.com](https://daneshyari.com)